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Defining the Optimal Dose of Rifapentine for
Pulmonary Tuberculosis: Exposure–Response
Relations From Two Phase II Clinical Trials
RM Savic1, M Weiner2,3, WR MacKenzie4, M Engle3, WCWhitworth4, JL Johnson5,6, P Nsubuga6,
P Nahid7,8, NV Nguyen8, CA Peloquin9, KE Dooley10, SE Dorman10
for the Tuberculosis Trials Consortium of the Centers for Disease Control and Prevention
Rifapentine is a highly active antituberculosis antibiotic with treatment-shortening potential; however, exposure–response
relations and the dose needed for maximal bactericidal activity have not been established. We used pharmacokinetic/
pharmacodynamic data from 657 adults with pulmonary tuberculosis participating in treatment trials to compare rifapen-
tine (n5 405) with rifampin (n5 252) as part of intensive-phase therapy. Population pharmacokinetic/pharmacodynamic
analyses were performed with nonlinear mixed-effects modeling. Time to stable culture conversion of sputum to negative
was determined in cultures obtained over 4 months of therapy. Rifapentine exposures were lower in participants who were
coinfected with human immunodeficiency virus, black, male, or fasting when taking drug. Rifapentine exposure, large lung
cavity size, and geographic region were independently associated with time to culture conversion in liquid media. Maximal
treatment efficacy is likely achieved with rifapentine at 1,200 mg daily. Patients with large lung cavities appear less respon-
sive to treatment, even at high rifapentine doses.
Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE
TOPIC?
 Rifapentine is a highly active antituberculosis antibiotic with
possible treatment-shortening potential. However, it is not clear
what are the exposure–response relations, the dose with maxi-
mal bactericidal activity, and which patients are unlikely to
respond to short-term treatment.
WHAT QUESTION DID THIS STUDY ADDRESS?
 This pharmacokinetic/pharmacodynamic study investigated
the dose of rifapentine with the greatest treatment-shortening
potential and the profile of patients unlikely to adequately
respond to reduced therapy.
WHAT THIS STUDY ADDS TO OUR KNOWLEDGE
 Rifapentine exposures were lower in participants with HIV
infection or who were black, male, or fasting. Optimal treat-
ment efficacy with satisfactory safety in the study was achieved
with 1,200-mg daily rifapentine. Rifapentine exposure, large
lung cavity, and geographic region were independently associat-
ed with time to culture conversion in liquid media. Patients
with large lung cavities appeared less responsive to rifapentine
treatment, even at high doses.
HOW THIS MIGHT CHANGE CLINICAL PHARMA-
COLOGY OR TRANSLATIONAL SCIENCE
 Pharmacokinetic/pharmacodynamic results supported level
rifapentine dosing in adults and further evaluation of rifapen-
tine at high daily doses as a TB treatment-shortening strategy.
Development of better treatment for tuberculosis (TB) is an
urgent global health need.1 Rifamycins have concentration-
dependent activity against Mycobacterium tuberculosis in vitro and
in murine models.2 In a phase II trial comparing rifapentine to
rifampin administered 5 days per week as part of a multidrug
intensive-phase therapy, the proportions of participants with
stable sputum culture conversion to negative were similar after
completion of 8 weeks of therapy.3 In a subsequent trial, antimi-
crobial activity and tolerability were evaluated with rifapentine
doses of 10, 15, or 20 mg/kg administered 7 days per week with
food.4 After 8 weeks of treatment, the proportions of stable cul-
ture conversions in liquid media were higher with rifapentine
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than rifampin; however, the study was not powered to compare
efficacy across rifapentine groups, and the optimal dose for test-
ing in phase III trials could not be established.
Sputum culture conversion to negative after completion of 2
months of intensive-phase treatment is a widely used efficacy bio-
marker in phase II TB treatment trials.5,6 However, this biomark-
er may not predict drug efficacy reliably in phase III trials.7–9 In
addition, using a binary outcome measure of efficacy does not
maximize use of the rich, longitudinal data, including serial
microbiologic outcome measures and drug exposure data.10 Fur-
thermore, clinical trials have not rigorously compared results
obtained from solid medium cultures with those obtained from
more sensitive liquid medium cultures.
Optimal drug dose and frequency can be efficiently estimated
with population pharmacokinetic/pharmacodynamic (PK/PD)
modeling methods that combine data on pharmacokinetic prop-
erties and efficacy outcomes.11,12 The main objectives of this PK/
PD study were to identify the rifapentine regimen that has the
greatest potential to shorten the duration of TB treatment, and
to describe a profile of patients unlikely to respond to shorter-
term therapy. To achieve the objectives, we characterized the
population pharmacokinetics of rifapentine in participants with
pulmonary TB treated with rifapentine as part of multidrug ther-
apy and established the PK/PD relation between rifapentine
exposure and time to stable sputum culture conversion.
RESULTS
Study population
Of the 668 adults who had smear-positive pulmonary TB in the
modified intention-to-treat group of TB Trial Consortium Studies
29 and 29X, 11 (1.6%) were excluded from the analysis due to
missing liquid culture data. Of the remaining 657 participants, 405
participants who had been treated with rifapentine during
intensive-phase therapy were included in the PK/PD analyses and
252 participants who had been treated with rifampin during
intensive-phase therapy were included in pharmacodynamic analy-
ses (Table 1).13 For 383 participants (95%), rifapentine pharmaco-
kinetic parameters were computed using plasma concentrations.
For the remaining 22 participants (5%) treated with rifapentine,
pharmacokinetic values were estimated using model parameters
and individual covariates (see Supplementary Table S1 and Sup-
plementary Figure S1). The rifampin and rifapentine groups were
similar in age, place of birth, race, and clinical features except that
the rifapentine group had a higher frequency of sparse pharmacoki-
netic testing and lower Karnofsky score (Table 1).
Rifapentine pharmacokinetic properties
Estimated model-based pharmacokinetic parameters for rifapentine
are shown in Table 2. Rifapentine area under the concentration–
time curve from 0–24 h (AUC0-24) and peak concentration
increased with increasing daily dose (Table 3). Age and sex
(Table 2 and Supplementary Table S2), but not body weight
(Supplementary Figure S2), were significant covariates of appar-
ent oral clearance. The AUC0-24 increased 0.4% per year in age.
Compared with a 450-mg dose, bioavailability decreased 9%, 17%,
and 26% with rifapentine doses of 600, 900, and combined 1,200
and 1,500 mg (comparison of four doses using log-likelihood ratio
test with 3 degrees of freedom; P 5 0.004). Other significant cova-
riates that affected bioavailability included race (Asian, 50%
increase compared with black race; P  0.0001) and human immu-
nodeficiency virus (HIV) infection (15% decrease; P 5 0.001)
(Table 2). For the same rifapentine dose, models suggested that the
lowest rifapentine exposures would occur in younger (continuous
variable), black, male participants taking rifapentine without food
(Supplementary Figure S3). Interindividual variability in rifapen-
tine AUC0-24 was high (coefficient of variance (CV) of 21%),
resulting in more than 4-fold variation in rifapentine exposures for
a given dose.
Rifapentine PK/PD modeling
Time to stable conversion on either liquid or solid media was
highly correlated with both rifapentine AUC0-24 and peak con-
centration (Figure 1). Time to stable conversion was best
described with a Weibull model with increasing probability (haz-
ard) of culture conversion with time. The pharmacokinetics-
based predictors were related to the hazard parameter (P <
0.001), and participants with high AUC0-24 or peak concentra-
tion showed significantly decreased treatment time to achieve sta-
ble culture conversion (Figure 1 and Supplementary Figure
S4).
Because of the high interindividual variability in rifapentine
AUC0-24 for a given dose used in this study, no significant rela-
tion was found between stable culture conversion in liquid media
and rifapentine study arm (doses: 10, 15, or 20 mg/kg; P 5 0.62)
or between stable culture conversion in liquid media and fixed
rifapentine doses (range, 450–1,500 mg daily; P 5 0.39) (Sup-
plementary Table S3).
Liquid media rifapentine PK/PD modeling
Estimated rifapentine AUC0-24 >350 lg 3 h/mL predicted maxi-
mum treatment efficacy in most patients (Table 4). Daily rifapen-
tine AUC0-24 >350 lg 3 h/mL was associated with stable
conversion to negative sputum cultures in liquid media within
12.4 weeks (95% confidence interval (CI), 11.1–14.2 wk) of daily
treatment in 95% of participants with no or small lung cavities;
however, for the group with large lung cavities, the estimated time
required for 95% of participants to achieve stable conversion was
>16 weeks (mean, 18.6 wk; 95% CI, 15.7–22.7 wk) (Table 4).
Significant independent covariates in models evaluating stable cul-
ture conversion in liquid media were rifapentine AUC0-24, lung
cavity aggregate diameter ( or <4 cm), geographic region of
study site (Africa vs. non-African region), and Karnofsky score
(Table 4 and Supplementary Table S4). In participants who had
cavities 4 cm, higher exposure did not reduce the estimated aver-
age time to stable culture conversion (Table 4, Figures 1 and 2).
Solid media rifapentine PK/PD modeling
Significant independent covariates of time to stable culture con-
version on solid media were rifapentine AUC0-24, baseline aggre-
gate lung cavity diameter ( or <4 cm) on chest radiographs,
grade of acid-fast bacilli smear of baseline sputum, and food
intake with study drug. Covariates that affected treatment
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Table 1 Demographic, clinical, and sampling characteristics of study participants with culture results in liquid media
Characteristic
Rifampin
n5 252 (38%)
Rifapentine
n5 405 (62%) Total P a
Demographic factors
Age (y) 33.0 (31.0, 36.0) 31.0 (29.0, 33.0) 32.0 (31.0, 33.0) NS
Place of birth NS
Africa 140 (56%) 221 (55%) 361 (55%)
South/Central America 50 (20%) 59 (15%) 109 (17%)
Asia/Pacific 30 (12%) 70 (17%) 100 (15%)
North America 20 (8%) 42 (10%) 62 (9%)
Europe 12 (5%) 13 (3%) 25 (4%)
Race NS
Black 149 (59%) 243 (60%) 392 (60%)
White 63 (25%) 76 (19%) 139 (21%)
Asian 30 (12%) 66 (16%) 96 (15%)
Other 1 (0.4%) 3 (0.7%) 4 (1%)
Not reported 9 (4%) 17 (4%) 26 (4%)
Sex, male 164 (65%) 286 (71%) 450 (68%) NS
Clinical data
Cavitation on chest radiograph NS
Cavities  4 cm total 92 (37%) 141 (35%) 233 (35%)
Cavities < 4 cm total 82 (33%) 137 (34%) 219 (33%)
No cavity 77 (31%) 127 (31%) 204 (31%)
Dose, rifapentine Not applicable
10 mg/kg 0 (0%) 284 (70%) 284 (43%)
15 mg/kg 0 (0%) 65 (16%) 65 (10%)
20 mg/kg 0 (0%) 56 (14%) 56 (9%)
HIV positive 34 (13%) 35 (9%) 69 (11%) NS
Weight (kg) 54.9 (53.5, 55.8) 55.0 (53.7, 56.7) 55.0 (54.0, 55.8) NS
Body mass index (kg/m2) 19.7 (19.2, 20.4) 19.8 (19.4, 20.2) 19.8 (19.5, 20.1) NS
Pharmacokinetic testing 0.0001
Intensive (6-7 samples) 13 (100%)b 79 (25%)b 92 (14%)
Sparse (1-3 samples) 0 (0%)b 237(75%)b 237 (36%)
Karnofsky score 0.02
100 37 (15%) 36 (9%) 73 (11%)
 90 215 (85%) 369 (91%) 584 (89%)
Cough before treatment NS
Productive 224 (89%) 365 (90%) 589 (90%)
Nonproductive 19 (8%) 26 (6%) 45 (7%)
No cough 9 (4%) 14 (3%) 23 (4%)
Sputum AFB smear gradec NS
41 (Highly bacillary) 98 (39%) 151 (38%) 249 (38%)
Table 1 Continued on next page
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response with rifapentine differed somewhat with solid culture
compared with liquid culture data (Supplementary Table S5).
We found that 95% of participants with rifapentine AUC0-24
>350 lg 3 h/mL and lung cavities <4 cm and those with
AUC0-24 >460 lg 3 h/mL and lung cavities 4 cm in aggregate
size (e.g., AUC95) achieved stable conversion on solid media after
completion of 2 months of daily treatment (Supplementary
Table S6 and Supplementary Figure S4). In contrast with the
exposure–response model using liquid media (Table 4, Supple-
mentary Figure S4), higher rifapentine exposures conferred
Table 1 Continued
Characteristic
Rifampin
n5 252 (38%)
Rifapentine
n5 405 (62%) Total P a
31 (Intermediate bacillary) 56 (22%) 96 (24%) 152 (23%)
11 (Paucibacillary) 85 (34%) 124 (31%) 209 (32%)
Negative 12 (5%) 31 (8%) 43 (7%)
Data reported as number (%) or median (interquartile range). AFB, acid-fast bacilli; HIV, human immunodeficiency virus.
aNS, not significant (P > 0.05). bPercentage in pharmacokinetic study participants. cAt least one positive sputum AFB smear during screening was required for enrollment,
but sputum smear status may have changed at the start of treatment (baseline). AFB sputum smear at baseline, quantified with light microscopy (Ziehl-Neelsen stain, origi-
nal magnification 31,000) and shown as follows: negative (none); grade 11 (1 per 100 fields to 9 per 10 fields); grade 31 (1 to 9 per field); and grade 41 (>9 per
field).15
Table 2 Estimated parameters for the integrated pharmacokinetic model for oral rifapentine in adults with tuberculosis
Parameter
Value
(RSE, %)
Between-subject
variability, CV% (RSE, %)
CL/F (L/h) 1.86 (5) 40 (15)
V/F (L) 12.77 (5) —
ka (h
-1) 0.07 (3) —
CLm/Fm (L/h) 1.91 (6) 44 (10)
Vm/Fm (L) 8.83 (12)
Bioavailability of 450-mg dose with high fat food (reference) 1 36 (11)
Bioavailability of 600-mg dose (fraction) relative to reference dose 0.91 (6)
Bioavailability of 900-mg dose (fraction) relative to reference dose 0.83 (6) —
Bioavailability of 1200-mg dose (fraction) relative to reference dose 0.74 (8) —
Fasting effect (vs. high fat) on bioavailability (fraction) 0.72 (7) —
Effect of low-fat food (vs. high-fat) on bioavailability (fraction) 0.83 (20) —
White (vs. black) race effect on bioavailability (fraction) 1.19 (36) —
Asian (vs. black) race effect on bioavailability (fraction) 1.51 (16) —
HIV infection (vs. HIV-uninfected) effect on bioavailability (fraction) 0.85 (44) —
Correlation CL-F 0.55 (21) —
Correlation CLm-F 0.45 (19) —
Correlation CL-CLm 0.69 (16) —
Age effect on CL (yearly decrease from the median age 31 y)a —0.00379 (50) —
Sex effect on CL (fraction in female vs. male) 0.81 (36) —
Dose effect (> 600 mg) on fraction metabolized, Fm (fraction) 1.34 (4) —
Proportional residual error, rifapentine (CV%) 19 (13) —
Additive residual error, rifapentine (lg/mL) 1.61 (28) —
Proportional residual error, metabolite (CV%) 14 (10) —
Additive residual error, metabolite (lg/mL) 1.33 (12) —
CL, clearance; CLm, clearance of desacetyl rifapentine; CV%, coefficient of variance; F, bioavailability; Fm, fraction metabolized; ka, absorption rate constant; m, metabolite
(desacetyl rifapentine); RSE, relative standard error; V, rifapentine volume of distribution.
aCL5 CL/F 3 (1 1 CLage3 [age (y) –31]).
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some benefit in patients with lung cavities 4 cm using solid cul-
ture data (see Supplementary Results, Supplementary Tables
S6 and S7, and Supplementary Figure S4). Stable culture con-
version on solid media required 52 to 62 days in 95% of partici-
pants with rifapentine exposure AUC95 (Supplementary
Table S6).
PK/PD modeling for safety endpoints
The event rates for evaluation of safety endpoints in participants
were: 18.9% (n 5 78) for rifapentine-related adverse events of
grade 3 and higher, and 15.6% (n 5 40) for rifampin-related
adverse events. The probability by logistic regression of partici-
pants experiencing grade 3 and higher adverse events was not
associated with rifapentine dose, AUC0-24 or Cmax (P > 0.05).
Similar results were obtained using a proportional odds model;
no significant relationships between grade of adverse events and
rifapentine dose or PK variables were observed (P > 0.05).
Achieving rifapentine target exposures
From clinical trial simulations of time-to-event maximal achiev-
able effect models using data from liquid culture, target rifapen-
tine AUC0-24 350 lg 3 h/mL (AUC95) was achieved with a
daily dose of rifapentine 1,200 mg in 87% of participants who
took drugs with high-fat foods, 73% of participants who took
study drugs with low-fat (<27 g) foods, and 64% of participants
who took study drugs when fasting. The rifapentine AUC0-24
achieved was higher with higher rifapentine doses and foods
higher in fat (Figure 3). To achieve target rifapentine exposures
in most participants with drug taken with or without food, it was
estimated that the rifapentine dose would need to be increased
to 1,800 mg daily in participants of black race and remain at
1,200 mg in other participants. With these adjusted rifapentine
doses, 96% of participants taking drug with high-fat food would
attain target AUC0-24 vs. 85% if drug was taken without food
(Supplementary Figure S5).
Rifampin pharmacodynamics
Covariates independently associated with outcome in the time-
to-event models for rifampin were extent of lung infiltrates and
baseline cough but not lung cavities (Table 4). For rifampin
models derived from data from liquid and solid cultures, the sig-
nificant covariates were the same (Supplementary Table S8).
The PK/PD outcomes were not directly comparable between
rifampin and rifapentine because rifampin pharmacokinetic sam-
pling was not performed, and lung cavitation was not a signifi-
cant independent covariate of stable culture conversion in
participants treated with rifampin. When compared with the par-
ticipant group treated with rifapentine with AUC0-24 350 lg
3 h/mL and with no or small lung cavities, all control partici-
pants treated with rifampin (Figure 1a, top arrow) were estimat-
ed to take an additional 3.7 weeks to develop stable culture
conversion to negative in liquid media. However, participants
with large cavities treated with rifapentine (irrespective of dose)
took an additional 2 weeks in liquid media to develop stable cul-
ture conversion to negative compared with all control partici-
pants treated with rifampin (Figure 1b, top arrow).
DISCUSSION
In this large PK/PD study, we identified a rifapentine dose that
may potentially shorten TB treatment and described a profile of
patients unlikely to respond to shorter-term treatment. In sup-
port of these objectives, we characterized the population pharma-
cokinetics of rifapentine in participants who had TB.
Interindividual variability of rifapentine was high. Although the
bioavailability of rifapentine decreased with increasing dose as
compared with the lowest dose administered (450 mg), high
exposures could be achieved when rifapentine was given daily at
high doses with food. Age and sex, but not body weight, affected
clearance, supporting the use of a single rifapentine dose in adults
with weights encountered in this study, rather than dosing based
on weight for the treatment of adults who have TB. Significant
predictors of lower exposures were fasting, black race, male sex,
Table 3 Relation between rifapentine daily dose, area under the concentration-time curve from 0 to 24 h, and peak concentrationa
Daily dose No. of participants
AUC0-24
(lg3 h/mL)
Cmax
(lg/mL)
Dose (mg)
450 60 2906 123 255 (153, 510) 14.76 5.8 13.8 (8.2, 26.3)
600 211 3246 143 295 (151, 579) 17.06 7.1 15.7 (7.7, 29.4)
900 78 4986 149 503 (272, 721) 25.16 7.0 24.4 (13.8, 36.3)
1200 30 5876 197 587 (317, 882) 29.96 9.1 31.4 (16.4, 43.1)
1500 4 6636 84 666 (572, 748) 33.26 3.3 33.0 (29.8, 36.8)
Dose (mg/kg)
10 236 3096 132 285 (154, 570) 16.16 6.6 15.0 (7.86 27.8)
15 74 4346 173 391 (203, 726) 22.16 8.2 20.5 (11.0, 35.7)
20 73 5466 176 538 (290, 832) 27.56 8.2 28.0 (15.2, 40.4)
AUC0-24, area under the concentration-time curve from 0 to 24 h; Cmax, peak concentration.
aData reported as mean 6 SD or median (5th, 95th percentile).
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younger age, and HIV coinfection. Food increased rifapentine
bioavailability by 40%, similar to that shown previously.14 Most
participants (73%) achieved target rifapentine exposures by tak-
ing the drug while consuming food.
To improve the proportion of patients achieving target expo-
sure, individualized rifapentine dosing regimens might be studied.
Lower rifapentine bioavailability was observed in black vs. other
participants, although race/region may have been confounded by
the food type (bulk, protein, carbohydrate as well as fat) taken
with study drug. Model simulations suggested that target rifapen-
tine exposures in 96% of all participants would be attained when
a very high daily dose of 1,800 mg rifapentine would be given
with high-fat food to black patients (or in 85% of all participants
who were fasting). However, high doses of rifapentine are not
well tolerated in healthy volunteers given rifapentine doses
of 900 to 1,800 mg daily with food.15 A rifapentine dose of
1,800 mg was not evaluated in the analyzed trials; however, rifa-
pentine 1,200 mg daily with food was well tolerated in trial par-
ticipants, no significant relationships between grade of adverse
events and rifapentine dose or PK variables were observed in this
PK/PD study, and target drug exposures were attained in most
participants. Only 34 participants received a rifapentine dose
1,200 mg in Study 29X; therefore, tolerability of higher doses
of rifapentine warrants further evaluation. With a pharmacody-
namic model of bactericidal activity, time to stable culture con-
version in liquid media was highly associated with rifapentine
exposure (P  0.001) but not with rifapentine dose used in this
study (10, 15, and 20 mg/kg). This demonstrates the utility of
PK/PD modeling to assess exposure–response relations and
inform dose selection for future trials.
In our study we identified subgroups that took longer than
others to convert their cultures to negative. Risk factors for slow
treatment response included high mycobacterial disease burden at
baseline, large lung cavities (4 cm), and enrollment from Afri-
can trial sites. African participants in this study exhibited multi-
ple features of more severe disease, including greater extent of
disease and cavitation on chest radiography, higher-grade acid-
fast bacilli smear in sputum, lower Karnofsky score, and lower
body mass index. Prior studies showed that risk factors for treat-
ment failure and relapse included more acid-fast bacilli in sputum
and greater radiographic extent of disease and cavitation.16–18
Furthermore, in two recent phase III trials to evaluate 4 months
of TB treatment (using rifamycin plus fluoroquinolone-
containing regimens), cavitary lung disease was a significant risk
factor for an unfavorable outcome.8,9 HIV coinfection in our
study was associated with a decrease in rifapentine bioavailability;
however, this was not a risk factor (independent of exposure) for
time to stable sputum culture conversion, similar to that shown
in previous studies.8,9
Rifapentine potency was markedly reduced in participants who
had extensive cavitary disease in our study (Table 4); no rifapen-
tine exposure–response relation was observed using liquid culture
data in this group. Prior studies in animal models of TB that pro-
duced lung pathology similar to human disease, with granuloma,
lung cavities, and caseation, similarly reported mixed results.19–21
Our results suggest that increased rifapentine exposure may not
improve culture conversion over standardized rifampin doses in
patients who have large lung cavities. Limited drug penetration
into severely affected lung tissue and cavitary lesions could con-
tribute to decreased efficacy.21 Although rifapentine demon-
strates satisfactory total concentrations in patient plasma, high
plasma protein binding (97–99%) reduces the free microbially
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Figure 1 Relation between rifapentine area under the concentration–time
curve from 0 to 24 h (AUC0-24) and maximum concentration (Cmax) vs. esti-
mated time required for 95% patients with no or small lung cavities (a) or
large lung cavities (b) to achieve stable conversion to negative sputum cul-
ture. Rifapentine AUC0-24 (gray) or Cmax (red) shown for liquid (continuous
line) and solid (broken line) culture media. Estimated time to stable culture
conversion for all control participants treated with rifampin during
intensive-phase therapy was 114 days in liquid media (top arrow) and 91
days on solid media (bottom arrow). Data for participants with large cavi-
ties on solid media were estimated for grade 4 acid-fast bacilli smear from
baseline sputum.
ARTICLES
326 VOLUME 102 NUMBER 2 | AUGUST 2017 | www.cpt-journal.com
active drug available for passive diffusion into the extravascular,
necrotic extracellular space of a large cavity with caseation.22
The recovery of M. tuberculosis from sputum in the present study
was greater using liquid than using solid media, similar to previous
studies.23,24 This may account for differences between PK/PD
models using the different media. As expected, model-predicted
time to stable culture conversion was shorter in solid than in liquid
media. Future phase III trials may evaluate whether factors associat-
ed with treatment response or target exposures are better predicted
by PK/PD models that use liquid vs. solid culture results.
The present study has several limitations. Rifapentine was
administered for only 8 weeks during intensive-phase therapy
and followed by rifampin in continuation-phase therapy in both
treatment trials. Further investigations are required to assess the
effects of rifapentine treatment beyond 8 weeks. Another
limitation of the PK/PD analyses was that only 34 participants
received a rifapentine dose 1,200 mg in the dose-ranging trial;
however, the robust pharmacokinetic analyses of 405 participants
receiving rifapentine treatment support our PK/PD findings.
Also, HIV-infected participants who were on antiretroviral thera-
py were underrepresented in this study. In addition, the pharma-
codynamic endpoints were assessed using time to stable culture
conversion during anti-TB treatment; participants were not fol-
lowed after treatment completion to assess long-term cure. A
final limitation was that concentrations of antitubercular drugs
other than rifapentine were not examined. However, study par-
ticipants received the same standard doses of nonrifamycin drugs
per protocol. The effect of all antitubercular drugs are now being
examined in a phase III randomized clinical trial of higher-dose
rifapentine administered for 4 months for tuberculosis treatment.
Table 4 Rifapentine and rifampin pharmacokinetic/pharmacodynamic outcomes in liquid media
Rifapentine pharmacokinetic/pharmacodynamic outcomesa
Rifapentine AUC0-24
a
(lg3 h/mL)
Aggregate cavity
size on chest
radiograph (cm)
Study site
in Africa
Percent participants with
negative cultures in liquid
media at completion of
intensive-phase therapy,
mean [95% CI]
Time (d) calculated for 50%
participants to develop stable
conversion to negative cultures
in liquid media while receiving
antituberculosis treatment
[range: 5%, 95% participants]
> 350 < 4 Yes 67 [53, 83] 45 [14, 88]
 4 Yes 40 [20, 56] 66 [20, > 120] b
< 4 No 79 [70, 87] 39 [12, 76]
 4 No 48 [30, 70] 57 [17, 111]
325 < 4 Yes 61 [44, 78] 48 [15, 94]
 4 Yes 36 [20, 56] 66 [20, > 120] c
< 4 No 73 [65, 83] 42 [13, 81]
 4 No 48 [30, 70] 57 [17, 111]
< 300 < 4 Yes 37 [27, 48] 68 [21, > 120] c
 4 Yes 37 [25, 49] 68 [21, > 120] c
< 4 No 47 [28, 63] 58 [18, 114]
 4 No 44 [22, 72] 58 [18, 114]
Rifampin pharmacodynamic outcomesd
Extent of lung infiltrate
on chest radiographd
Productive
cough at baseline
Percent of participants with negative
cultures in liquid media at completion
of intensive-phase therapy, mean [95% CI]
Time (d) calculated for 50%
participants to develop negative
cultures in liquid media while
receiving antituberculosis treatment
[range: 5%, 95%]
< 25% Yes 67 [55, 79] 46 [16, 85]
No 93 [72, 100] 32 [11, 58]
 25% Yes 37 [30, 45] 66 [22, 122]
No 68 [42, 92] 45 [15, 84]
aAUC0-24 computed as rifapentine dose/CL, and the AUC0-24 targets refer to daily drug administration 7 days/week. Estimates of rifapentine AUC95 and inspection of
Figure 1 and Supplementary Figure S4 were used to formulate target rifapentine AUC0-24 cutoffs of >350 and <300 lg 3 h/mL. Participants with Karnofsky score 90
are grouped by the significant covariates of rifapentine exposure, aggregate cavity size on chest radiograph, and geographic origin of study site. To more simply display the
most relevant pharmacokinetic/pharmacodynamic data from most of the study participants, data for 38 participants with Karnofsky score of 100 are separately presented
in Supplementary Table S4. Proportion of participants with estimated treatment time >120 days were 7.7% (b) and 8.8% (c). AUC0-24, area under the concentration-time
curve from 0 to 24 h; AUC95, area under the concentration-time curve to achieve stable conversion in 95% of participants; CI, confidence interval; CL, clearance.
dPartici-
pants grouped by the significant covariates of percentage area of extent of lung infiltrate on chest radiograph and baseline cough with or without sputum production.
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Strengths of the present study included the data collection as a
component of two rigorously conducted clinical trials done at
sites in Asia, Africa, North America, and Europe that compared
rifapentine- to rifampin-based intensive-phase treatment admin-
istered by directly observed therapy. The pharmacokinetic sam-
ples were collected using standardized procedures and assayed by
one laboratory. Furthermore, a novel PK/PD analytic model
demonstrated proof of principle to establish rifapentine
exposure-efficacy response relations.
In summary, the present pharmacokinetic study supports level
dosing of rifapentine in adults (dosing in mg instead of mg/kg)
because rifapentine clearance was not affected within a range of
common adult weights (aged 18 years and older). The PK/PD
modeling demonstrated significant exposure–response relations.
Risk factors for low rifapentine concentrations and reduced
response to treatment were identified.
The potential utility of treatment shortening with rifapentine
is unknown. The PK/PD model simulations suggested that stable
sputum culture conversion can be achieved after completion of 4
months of therapy in most participants who have no or small
lung cavities and who are treated with rifapentine 1,200 mg daily
with food as part of multidrug therapy. However, the PK/PD
analyses suggested poorer outcomes in patients with large lung
cavities and highly positive sputum smears. These results support
further evaluation of rifapentine at high daily doses as a TB
treatment-shortening strategy, with special attention to sub-
groups at higher risk of suboptimal rifapentine exposures and
reduced response to therapy.
METHODS
Study design
We evaluated adults who had smear-positive pulmonary TB enrolled in
two randomized phase II clinical trials that compared rifapentine with
rifampin during the first 8 weeks of anti-TB therapy (TB Trial Consor-
tium Studies 29 and 29X) conducted in Brazil, Hong Kong, Kenya,
Peru, South Africa, Spain, Vietnam, Uganda, and the United States.3,4
In both studies, rifapentine was given as 150-mg tablets (Priftin, Sanofi-
Aventis, Anagni, Italy). Participants also received isoniazid, pyrazina-
mide, and ethambutol in weight-based doses during the initial 8 weeks
of treatment, in accordance with published guidelines.25 In both studies,
participants were treated during the continuation-phase with rifampin
and isoniazid according to published guidelines.25 Methods and results
0 50 100 150
Median time (days) to culture conversion (95% CI)
High RPT AUC, non−African, small or no lung cavity
High RPT AUC, African, small or no lung cavity
High RPT AUC, non−African, large lung cavity
High RPT AUC, African, large lung cavity
Low RPT AUC, non−African
Low RPT AUC, African
RHZE, high X−ray extent of disease, productive cough
RHZE, low X−ray extent of disease, productive cough
39 [ 12 ,  76 ]
45 [ 14 ,  88 ]
57 [ 17 , 111 ]
66 [ 20 , 129 ]
58 [ 18 , 144 ]
67 [ 21 , 132 ]
66 [ 22 , 122 ]
46 [ 16 ,  85 ]
Figure 2 Forest plot of the relative effects of demographics, clinical covariates, and rifapentine area under the concentration–time curve from 0 to 24 h
(AUC0-24) on outcome of time (d) to culture conversion of sputum in liquid media culture. Median and 95% confidence interval are indicated by the square
box and bars. Covariate effects are shown in patients taking rifampin-based intensive-phase therapy in the control group. Low (high) rifapentine (RPT)
AUC, target rifapentine AUC0-24 <300 (>350) lg 3 h/mL (AUC0-24 from daily drug administration 7 days per week); low (high) radiographic extent of dis-
ease, <50% (50%) lung area by baseline chest radiograph; productive cough, productive cough at entry into the phase IIB treatment trials; large lung
cavity (small or no lung cavity) on radiograph, aggregate size 4 cm (<4 cm); RHZE, Control regimen during intensive-phase therapy of rifampin (R), isoni-
azid (H), pyrazinamide (Z), and ethambutol (E); RPT, rifapentine.
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from both trials have been published.3,4 Both trials were registered at
ClinicalTrials.gov (NCT00694629 and NCT01043575).
In Study 29, participants were randomized to receive rifapentine
(10 mg/kg/dose) or rifampin (10 mg/kg/dose) 5 days per week for
8 weeks (intensive-phase), and doses were taken on an empty stomach.3
In Study 29X, participants received rifampin (10 mg/kg/dose) or rifa-
pentine (10, 15, or 20 mg/kg/dose) once daily with food, 7 days per
week, for 8 weeks, and food consumption before PK sampling was docu-
mented with food histories (see Supplementary Methods).
The PK/PD analysis included participants from the modified
intention-to-treat group (individuals with culture-confirmed M. tubercu-
losis) from both treatment studies. This study was approved by the Insti-
tutional Review Boards of the United States Centers for Disease
Control and Prevention and participating sites. Informed consent was
obtained from all participants.
Rifapentine and desacetyl rifapentine assays and
pharmacokinetic data
Blood samples were collected in either a sparse (1–3 samples per partici-
pant) or an intensive (7 samples per participant) pharmacokinetic sam-
pling visit, conducted after 2 but 8 weeks of anti-TB treatment
(Supplementary Methods and Results). Plasma concentrations of rifa-
pentine and its desacetyl rifapentine metabolite were determined using a
validated high-performance liquid chromatography assay (Pharmacoki-
netics Laboratory, University of Florida, Gainesville, FL).26
Microbiologic data
Sputum specimens were collected before the start of study therapy (base-
line), after completion of 2, 4, 6, 8, and 12 weeks of treatment, and then
monthly during continuation-phase treatment unless any two consecu-
tive prior sputum samples were documented as culture-negative.3,4
Population pharmacokinetic/pharmacodynamic modeling
Data were analyzed using a nonlinear mixed-effects approach with soft-
ware (NONMEM, v. 7, ICON, Dublin, Ireland) (Supplementary
Methods and Supplementary Figure S1). For PK/PD modeling, indi-
vidual AUC values from participants in Study 29 were adjusted
(decreased by 28.6%) to account for drug administration on 5 of 7 days
per week, compared with participants in Study 29X, where drugs were
administered 7 days per week. Efficacy endpoints were characterized
using serial sputum culture results on both solid and liquid media. Stable
culture conversion was defined as conversion of sputum cultures from
positive to negative during anti-TB therapy in two consecutive sputum
cultures. Efficacy endpoints used in exposure–response models included
1) percentage of participants who had negative sputum cultures at com-
pletion of intensive-phase therapy and 2) days of anti-TB treatment
required for stable culture conversion. The latter was used to develop
maximum effect time-to-event models. Covariates tested in exposure–
response models included age, sex, weight, race, HIV status, body mass
index, the summed diameter of all cavitary lesions on pretreatment chest
radiographs, extent of lung infiltrate, baseline sputum smear grade,
cough, and Karnofsky score (Supplementary Table S1). Covariates
were tested on the following model parameters: maximal achievable
effect, rifapentine area under the concentration–time curve to achieve
50% (AUC50) maximal achievable effect, and hazard function defined
by scale and shape parameters (Supplementary Methods). Most culture
conversion data in the PK/PD model were collected within the first 4
months of treatment; therefore, model predictions and simulations were
restricted to 120 days to increase reliability.
Development of the pharmacokinetic/pharmacodynamic
models
To describe the time to stable culture conversion, a parametric survival
function was used, according to the equation:
St5e
2
Ð t
0
hðtÞdðtÞ
The hazard was ht, and the survival St was a function of the cumulative
hazard from time 0 to time t describing the probability of not converting
the culture to negative within this time interval. The base model was
developed by exploring different functions for the hazard ht, starting
from a simple time-independent constant hazard and gradually progress-
ing to more complex functions, including Weibull function according to
the equation:
ht5h0gðh0tÞg21
where h0 was baseline hazard at time 0 and c was a shape parameter.
Model building was guided by the likelihood ratio test, diagnostic
plots, and internal model validation techniques, including visual and
numeric predictive checks. Additional details for development of the
PK/PD models and rifapentine and rifampin PK/PD model parame-
ters are described in the Supplementary Methods (Supplementary
Table S3).
Data from participants receiving rifampin were used for comparison
in clinical trial simulations (Supplementary Methods).
Additional Supporting Information may be found in the online version of
this article.
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